Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.

Trial Profile

Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2017 Primary endpoint (Disease activity score ) has been met as per results published in the Annals of the Rheumatic Diseases.
    • 22 Sep 2017 Status changed to discontinued due to change in the institution preference policy for biological disease-modifying anti-rheumatic drugs disease-modifying anti-rheumatic drugs decreasing the number of eligible patients,as per results published in the Annals of the Rheumatic Diseases.
    • 22 Sep 2017 Results published in the Annals of the Rheumatic Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top